PreADx Alzheimer’s Detection Immunoassay Proof of Concept Study Successful
Unlike plasma or serum-based assays, PreADx takes an intracellular approach and measures the clearance of beta-amyloid peptides by analyzing a patient’s monocytes.
Unlike plasma or serum-based assays, PreADx takes an intracellular approach and measures the clearance of beta-amyloid peptides by analyzing a patient’s monocytes.
The ultrasensitive test uses samples of cerebrospinal fluid to detect abnormal forms of the protein tau associated with uncommon types of neurodegenerative diseases called tauopathies.
XRGenomics is using Affymetrix technology to develop gene expression-based signatures for translational research and biomarker test development in areas such as dementia, Alzheimer’s, and other age-related diseases.
Amarantus BioScience Inc announced that it has licensed the LymPro Alzheimer’s Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences Inc.
Read MoreMetabolic studies could lead to new therapies, says a Tel Aviv University researcher.
Read MoreVista Clinical Diagnostics offers the industry’s most advanced testing, and recently introduced a partnership program for smaller and medium-size labs. Davian Santana, president, and Nathan Hawkins, vice president. What if your favori
Read Morehe Alzheimer’s Challenge 2012 calls for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer’s disease.
Read MorePositive Early Results for Parkinson’s Treatment Michael J. Fox Harbor BioSciences, San Diego, which is investigating the use the company’s proprietary compound Triolex as a treatment for Parkinson’s disease (PD) with fund
Read MoreBiOasis announces completion of a project intended to produce proprietary monoclonal antibodies for its Cognitest blood test for Alzheimer’s disease.
Read MoreFive Flutemetamol abstracts featured at the 2011 Human Amyloid Imaging meeting.
Read MoreAmsterdam Molecular Therapeutics to supply cGMP manufacturing to consortium led by Institut Pasteur for clinical development of therapy for rare genetic disorder in children (pictured: AMT CEO Jorn Aldag).
Read MoreRadient Pharmaceuticals Corp (RPC) announced that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines.
Read MoreGold Standard Diagnostics Inc (GSD) announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the US Market.
Read MoreVermillion Inc, a molecular diagnostics company, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled “Biomarkers for Alzheimer’s disease” to the company.
Read MorePower3 Medical Products Inc announces that it has discovered new findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with widely used anti-dementia drugs.
Read MoreFoundation Venture Capital Group hopes to help to lower the number of people living with Alzheimer’s disease. The company has made an initial investment to Durin Technologies Inc., a start-up company developing a test that requires only a drop of blood to diagnose the disease.
Read MoreScott and White Temple Hospital physician Arden L. Aylor, MD is one of three North American physicians who will help in the development and adoption of standard guidelines regarding dementia at the World Health Organization’s World Conference.
Read MoreSeveral cerebrospinal fluid (CSF) biomarkers showed good accuracy in identifying patients with mild cognitive impairment who progressed to Alzheimer disease, according to a study in the July 22/29 issue of JAMA.
Read More